-- Medicenna Brief: Presenting Preclinical Data from its Anti-PD1-IL-2 BiSKIT and IL-2 Super Agonist Programs at 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)
10:00 AM EST, 11/08/2024 (MT Newswires) --
Price: 2.30, Change: -0.17, Percent Change: -6.88